Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update
Provided By GlobeNewswire
Last update: Aug 12, 2025
Reached full enrolment of Phase 1b study evaluating GT-02287 in Parkinson’s Disease (PD) with or without GBA1 mutations during 2Q 2025, earlier than anticipated
Analysis of functional changes and biomarker activity at 90 days will be available during 4Q 2025
Read more at globenewswire.com
